VANGUARD GROUP INC - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 94 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$12,163,899
-19.6%
2,231,908
+0.2%
0.00%
Q2 2023$15,121,392
+32.3%
2,227,009
-2.4%
0.00%
Q1 2023$11,427,820
+3.7%
2,281,002
+1.0%
0.00%
Q4 2022$11,020,280
-60.2%
2,258,254
+17.6%
0.00%
-100.0%
Q3 2022$27,693,000
-5.2%
1,920,421
-0.5%
0.00%0.0%
Q2 2022$29,200,000
+37.0%
1,929,916
+7.5%
0.00%0.0%
Q1 2022$21,319,000
-27.6%
1,794,510
-1.2%
0.00%0.0%
Q4 2021$29,455,000
-42.8%
1,817,074
+0.7%
0.00%0.0%
Q3 2021$51,485,000
-6.9%
1,803,924
+10.3%
0.00%0.0%
Q2 2021$55,272,000
+14.3%
1,635,255
+2.3%
0.00%0.0%
Q1 2021$48,341,000
-34.1%
1,598,579
+7.9%
0.00%
-50.0%
Q4 2020$73,326,000
+53.5%
1,481,033
+19.0%
0.00%0.0%
Q3 2020$47,769,000
-10.8%
1,244,290
+0.4%
0.00%0.0%
Q2 2020$53,553,000
+89.7%
1,239,664
+14.6%
0.00%
+100.0%
Q1 2020$28,232,000
-14.4%
1,081,658
+2.5%
0.00%0.0%
Q4 2019$32,975,000
+70.3%
1,055,197
+42.0%
0.00%0.0%
Q3 2019$19,362,000
+72.9%
742,982
+51.8%
0.00%
Q2 2019$11,196,000
+50.1%
489,582
+72.0%
0.00%
Q1 2019$7,459,000
+42.6%
284,561
+10.6%
0.00%
Q4 2018$5,232,000
+131.5%
257,265
+202.3%
0.00%
Q3 2018$2,260,00085,1000.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 191,176$2,271,0002.63%
Sofinnova Investments, Inc. 2,194,278$26,068,0001.98%
MPM BioImpact LLC 443,702$5,271,0001.42%
Soleus Capital Management, L.P. 238,982$2,839,0000.37%
Lombard Odier Asset Management (Switzerland) SA 221,774$2,635,0000.21%
Artal Group S.A. 400,000$4,752,0000.20%
Polar Capital Holdings Plc 2,877,671$34,187,0000.15%
ASHFORD CAPITAL MANAGEMENT INC 106,770$1,268,0000.14%
Cormorant Asset Management, LP 150,000$1,782,0000.14%
Virtus ETF Advisers LLC 23,646$281,0000.13%
View complete list of Y-MABS THERAPEUTICS INC shareholders